{
    "nctId": "NCT04511871",
    "briefTitle": "A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors",
    "officialTitle": "A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer, Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "MTD: to determine the maximum tolerated dose of CCT303-406",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with willingness to be in the study and follow all study procedures, and capable of providing informed consent\n2. Male or female aged 18-70 years\n3. Patients with stage IV (according to the 8th edition of AJCC) advanced solid tumor malignancies that have failed standard treatment of relapsed or difficult-to-treat solid tumors confirmed by histology or cytology\n4. At least one measurable lesion, i.e. the length of non-lymph node lesions examined according to CT cross-sectional scanning or magnetic resonance imaging (MRI), or the short diameter of the lymph node lesions is \u226515 mm according to RECIST 1.1\n5. Tumors with HER2 IHC 3+ in\u226550% of all tumor cells as determined by IHC according to the Breast Cancer HER2 Testing (2019 edition) and the Gastric Cancer HER2 Testing (2016 edition); For HER2 IHC 3+ tumors other than gastric and breast cancers, FISH is required to confirm HER2 expression; For relapsed patients after HER2-targeted therapies, biopsy and IHC are required to confirm HER2 expression per enrollment criteria.\n6. ECOG Performance Status 0-1\n7. Expected survival greater than 12 weeks\n8. Adequate organ and hematopoietic system functions to meet the following requirements:\n\n   * Hemoglobin (HGB) s 90 g/L, no blood transfusions within two weeks;\n   * White blood cell (WBC) count\u22652.5\u00d7109/L\n   * Absolute Neutrophil Count (ANC) \u22651.5 x 109/L\n   * Platelet (PLT) count \u226580-109/L\n   * Total bilirubin (TBIL) \u22643.0ng/dL or \u22645 ULN\n   * ALT and AST \u22645 ULN; for liver metastasis, ALT and AST \u22645 ULN\n   * Creatinine (Cr) \u22641.5 x ULN; or creatinine removal rate (CrCl) \u226550 mL/min\n9. LVEF\u226550%\n10. Serum troponin T \\<0.03 ng/mL\n11. PT: INR \\< 1.7 or extended PT to normal value \\< 4s\n12. Normal language, recognition and consciousness assessed by investigator during screening phase\n13. Capable of receiving treatment and follow-up, including treatment in the clinical center;\n14. Female subjects of childbearing age must take acceptable measures to minimize the likelihood of pregnancy during the trial. The results of serum or urine pregnancy test must be negative\n15. Female subjects must not be in the lactation period.\n\nExclusion Criteria:\n\n1. Females with pregnancy or in lactation period\n2. Patients with active hepatitis B, or active hepatitis C\n3. HIV positive\n4. Other active infections of clinical significance\n5. Patients receiving in situ surgery within 3 months\n6. Patients with the following previous or accompanying diseases:\n\n   \u2022 Patients diagnosed as severe autoimmune diseases that require long term (more than 2 months) treatment with systemic immunosuppressants (steroids), or diseases with immune-mediated symptoms, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis\n7. Patients with \u2265Grade 2 peripheral neuronal diseases (according to NCI-CTCAE v5.0)\n8. Patients with any mental illness, including dementia, mental changes, which may cause difficulties understanding the informed consent and related questionnaires\n9. Patients with serious uncontrollable diseases, which may interfere with the therapies in this study\n10. Patients with other active malignancies in the past 5 years excluding those with completely cured basal or squamous skin cancers, superficial bladder cancers or primary breast cancers without need of follow-up treatment\n11. Patients receiving systemic steroids or steroid inhalants\n12. Patients who have received tumor immunotherapy (including monoclonal antibody or cell therapy) in the past 4 weeks\n13. Patients allergic to immunotherapies or related drugs\n14. Patients with metastatic lesions in meninges or central nervous system, or clear evidence of central nervous system diseases with continous significant symptoms in the last 6 months\n15. Patients with NYHA class II heart failure, or hypertension incontrollable by standard care, or medical history of myocarditis, or heart attack within a year\n16. Patients who have received or are going to receive organ transplantation\n17. Patients with active bleeding\n18. Patients with incontrollable pleural or abdominal fluid that needs clinical treatment or intervention\n19. Patients having undergone major surgery within 4 weeks or have not fully recovered from prior surgery\n20. Patients that have received radiotherapy within 4 weeks, excluding those who received local irradiation for the peripheral bone metastatic lesions for more than 2 weeks, and recovered from all acute toxicities of radiotherapy\n21. Patients that have received anthracyclines within 8 weeks\n22. Patients as determined by the investigators to be inappropriate for the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}